Advertisement

Breast Cancer Research and Treatment

, Volume 171, Issue 3, pp 737–745 | Cite as

Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort

  • Ji-Yeon Kim
  • Ji Eun Lim
  • Hae Hyun Jung
  • Soo Youn Cho
  • Eun Yoon Cho
  • Se Kyung Lee
  • Jong Han Yu
  • Jeong Eon Lee
  • Seok Won Kim
  • Seok Jin Nam
  • Yeon Hee Park
  • Jin Seok Ahn
  • Young-Hyuck ImEmail author
Epidemiology

Abstract

Purpose

The new eighth edition TNM classification by the AJCC for breast cancer (BC) incorporates biologic factors and gene expression prognostic panels, in addition to traditional anatomic factors. In this study, we evaluated the prognostic value of this new staging system compared to the previous AJCC 7th edition staging system.

Methods

We conducted a retrospective analysis of women with stage I, II, or III BC who underwent curative surgery with/without adjuvant systemic therapy at Samsung Medical Center between July 2004 and December 2008.

Results

Of 3,208 BCs, this study was analyzed using the information of 2,790 BC patients. Hormone receptor-positive (HR+) and human epidermal growth factor 2 (HER2)− BCs were observed in 62.9% of BCs, HR+/ HER2+ in 9.3%, HR−/HER2− in 17.0%, and HR−/HER2+ in 10.8%. In survival analysis, we observed 245 distant recurrences and 198 deaths caused by BC progression. The median follow-up duration was 116.2 months. 10-year disease-specific survival (DSS) rates according to the AJCC 7th edition criteria were 97.2% of stage IA, 100% of IB, 94.9% of IIA, 87.9% of IIB, 86.4% of IIIA, 95.7% of IIIB, and 65.7% of IIIC (p < 0.001). After applying 8th edition criteria, the 10-year DSS rates were 98.1% of stage IA, 97.7% of IB, 93.8% of IIA, 92.7% of IIB, 88.2% of IIIA, 80.8% of IIIB, and 70.3% of IIIC (p < 0.001).

Conclusions

The AJCC 8th edition clinical staging system provides a good prognostic value and addresses the weakness of the AJCC 7th edition, which uses only anatomical pathologic staging.

Keywords

Breast cancer TNM staging AJCC 8th edition Immunohistochemistry 

Notes

Compliance with ethical standards

Conflict of interest

The authors have declared no conflicts of interest.

Ethical approval

The experiments comply with the current laws of the country in which they were performed.

References

  1. 1.
    Edge SBCC. (2009) The AJCC Cancer Staging Manual. 7th edn. Springer, New YorkGoogle Scholar
  2. 2.
    Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174–183.  https://doi.org/10.1016/S1470-2045(09)70262-1 CrossRefPubMedGoogle Scholar
  3. 3.
    Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41:154–161CrossRefPubMedGoogle Scholar
  4. 4.
    Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410CrossRefPubMedGoogle Scholar
  5. 5.
    Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005–2014.  https://doi.org/10.1056/NEJMoa1510764 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M, Investigators M (2016) 70-Gene Signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717–729.  https://doi.org/10.1056/NEJMoa1602253 CrossRefPubMedGoogle Scholar
  7. 7.
    Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M, Austrian B, Colorectal Cancer Study G (2013) EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol 24:640–647.  https://doi.org/10.1093/annonc/mds334 CrossRefPubMedGoogle Scholar
  8. 8.
    Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222–5232.  https://doi.org/10.1158/1078-0432.CCR-10-1282 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M (2013) Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14:1067–1076.  https://doi.org/10.1016/S1470-2045(13)70387-5 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, Group AT (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139CrossRefPubMedGoogle Scholar
  11. 11.
    Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol 25:486–492.  https://doi.org/10.1200/JCO.2006.08.8617 CrossRefPubMedGoogle Scholar
  12. 12.
    Trialists’ Collaborative EBreastC, Davies G, Godwin C, Gray J, Clarke R, Cutter M, Darby D, McGale S, Pan P, Taylor HC, Wang C, Dowsett YC, Ingle M, Peto J R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784.  https://doi.org/10.1016/S0140-6736(11)60993-8 CrossRefGoogle Scholar
  13. 13.
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684.  https://doi.org/10.1056/NEJMoa052122 CrossRefPubMedGoogle Scholar
  14. 14.
    Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC, American Society of Clinical O, College of American P (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48-72.  https://doi.org/10.1043/1543-2165-134.7.e48 PubMedCrossRefGoogle Scholar
  15. 15.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical O, College of American P (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013.  https://doi.org/10.1200/JCO.2013.50.9984 CrossRefPubMedGoogle Scholar
  16. 16.
    Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN (2017) Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67:290–303.  https://doi.org/10.3322/caac.21393 CrossRefPubMedGoogle Scholar
  17. 17.
    Abdel-Rahman O (2017) Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Res Treat.  https://doi.org/10.1007/s10549-017-4577-x CrossRefPubMedGoogle Scholar
  18. 18.
    Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK, Mittendorf EA (2017) Validation study of the American Joint Committee on Cancer eighth edition prognostic stage compared With the anatomic stage in breast cancer. JAMA Oncol.  https://doi.org/10.1001/jamaoncol.2017.4298 CrossRefGoogle Scholar
  19. 19.
    Hu H, Wei W, Yi X, Xin L, Liu Y (2017) A Retrospective analysis of clinical utility of AJCC 8th edition cancer staging system for breast cancer. World J Oncol 8:71–75.  https://doi.org/10.14740/wjon1039e CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Ji-Yeon Kim
    • 1
    • 2
  • Ji Eun Lim
    • 2
  • Hae Hyun Jung
    • 2
  • Soo Youn Cho
    • 3
  • Eun Yoon Cho
    • 3
  • Se Kyung Lee
    • 4
  • Jong Han Yu
    • 4
  • Jeong Eon Lee
    • 4
  • Seok Won Kim
    • 4
  • Seok Jin Nam
    • 4
  • Yeon Hee Park
    • 1
    • 2
  • Jin Seok Ahn
    • 1
  • Young-Hyuck Im
    • 1
    • 2
    Email author
  1. 1.Division of Hematology-Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  2. 2.Biomedical Research Institute, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  3. 3.Department of Pathology, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea
  4. 4.Department of Surgery, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulRepublic of Korea

Personalised recommendations